Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.21|
|52 Week High||US$3.68|
|52 Week Low||US$13.81|
|1 Month Change||-18.88%|
|3 Month Change||-0.71%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-29.83%|
Recent News & Updates
Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Ocuphire Pharma: An Undervalued Ophthalmic Play
Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications. The company recently announced positive topline results for its lead candidate, Nyxol, in a Phase 3 study for Reversal of Mydriasis (RM) and in a Phase 2 study for Presbyopia. The company is targeting multi-billion dollar market opportunities in four indications, which remain largely unmet, and in some cases with no approved therapies or competition.
|OCUP||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how OCUP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how OCUP performed against the US Market.
Stable Share Price: OCUP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OCUP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330.
Ocuphire Pharma Fundamentals Summary
|OCUP fundamental statistics|
Is OCUP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OCUP income statement (TTM)|
|Cost of Revenue||US$6.38m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.91|
|Net Profit Margin||-66,078.00%|
How did OCUP perform over the long term?See historical performance and comparison
Is Ocuphire Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCUP ($4.21) is trading below our estimate of fair value ($439.48)
Significantly Below Fair Value: OCUP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCUP is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: OCUP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCUP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCUP's PB Ratio (3.2x) is in line with the US Pharmaceuticals industry average.
How is Ocuphire Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCUP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCUP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCUP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCUP's revenue (92.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: OCUP's revenue (92.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCUP's Return on Equity is forecast to be high in 3 years time
How has Ocuphire Pharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: OCUP is currently unprofitable.
Growing Profit Margin: OCUP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if OCUP's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare OCUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: OCUP has a negative Return on Equity (-292.99%), as it is currently unprofitable.
How is Ocuphire Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: OCUP's short term assets ($25.2M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: OCUP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OCUP is debt free.
Reducing Debt: OCUP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OCUP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 88.7% each year.
What is Ocuphire Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCUP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCUP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCUP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCUP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCUP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mina Sooch (53 yo)
Ms. Mina Patel Sooch, MBA serves as Founder and Chief Executive Officer of Ocuphire Pharma, Inc. since October 2018 and serves as its President and Treasurer and serves as its Vice Chair of the Board since...
CEO Compensation Analysis
Compensation vs Market: Mina's total compensation ($USD483.07K) is about average for companies of similar size in the US market ($USD545.22K).
Compensation vs Earnings: Mina's compensation has been consistent with company performance over the past year.
Experienced Management: OCUP's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: OCUP's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCUP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: OCUP only recently listed within the past 12 months.
Ocuphire Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Ocuphire Pharma, Inc.
- Ticker: OCUP
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$71.135m
- Shares outstanding: 16.90m
- Website: https://www.ocuphire.com
Number of Employees
- Ocuphire Pharma, Inc.
- 37000 Grand River Avenue
- Suite 120
- Farmington Hills
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:52|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.